Use of an adenosine a3 receptor agonist for inhibition of viral replication
AssigneeCan-Fite Biopharma Ltd.
InventorsPnina Fishman, Kamel Khalili
Life of this patent
Estimating the term…
Abstract
The present invention concerns the use of an active ingredient selected from the group consisting of agonists of the adenosine receptor system, for inhibiting viral replication in cells. In particular, the invention provides a composition and method for inhibiting viral replication in cells, the method comprising presenting to the cells an effective amount of the active ingredient. According to one embodiment, the adenosine agonist is an A3 receptor agonist (A3RAg). The invention is particularly useful, for although not limited to, inhibiting the replication of HIV virus in human cells.
Claims19
A pharmaceutical composition for inhibiting replication of a virus inside cells comprising a pharmaceutically acceptable carrier and an effective amount of at least one adenosine A3 receptor agonist (A3RAg):
The pharmaceutical composition of claim 3, wherein said A3RAg is a nucleoside derivative of the general formula (IV):
- 10
- wherein X1, R2 R4 and R5 are as defined in claim 4.
Use of at least one adenosine A3 receptor agonist (A3RAg) for the preparation of a pharmaceutical composition for inhibiting replication of a virus together with pharmaceutically acceptable
A method for inhibiting replication of a virus in cells comprising contacting the cells with an effective amount of at least one adenosine A3 receptor agonist (A3RAg).
A method for inhibiting replication of a virus in cells of an individual administering to the individual an affective amount of at least one adenosine A3 receptor agonist (A3RAg).
Dependencies are inferred from the claim text.